Want to see PURE full AI Analyst Report?
PURE Stock Chart & Stats
$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)
Day’s Range― - ―
52-Week Range$0.04 - $0.14
Previous CloseN/A
Volume1.63K
Average Volume (3M)53.72K
Market Cap
$8.58M
Enterprise Value$12.84M
Total Cash (Recent Filing)$983.00K
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta-0.74
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding130,017,560
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.96
Price to Sales (P/S)4.56
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue5.30
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda69.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SDC TechnologyOwning a proprietary silver-based antimicrobial (SDC) platform is a durable competitive asset in food, institutional and sanitation markets. It supports product differentiation, potential licensing or recurring product sales, and long-term customer stickiness where validated antimicrobial performance matters.
Sustained Revenue RecoveryA ~62% TTM sales increase signals meaningful demand recovery and expanding commercial traction versus recent troughs. If sustained, this revenue base can enable scale, improve gross leverage on fixed costs, and underpin reinvestment into sales, R&D and distribution over the next several quarters.
Recent $1M Financing And Insider SupportThe $1.0M private placement improves near-term liquidity and shows insider confidence via board participation. This reduces immediate refinancing pressure, supports working capital and R&D spending, and provides a runway buffer while revenue trends continue to recover over the coming months.
Bears Say
Negative Stockholders' EquityNegative equity reflects accumulated losses that weaken the capital structure, limit borrowing capacity and reduce stakeholder flexibility. Over the medium term this raises refinancing and solvency risk, constrains strategic investments, and can pressure supplier and creditor terms if losses persist.
Persistent Cash BurnConsistent negative operating and free cash flow means the core business does not self-fund growth. Continued cash burn forces reliance on external financing, increasing dilution or leverage risk, and limits management's ability to invest in commercialization or scale without recurring capital raises.
Ongoing Unprofitability & Data AnomaliesPersistent operating losses and deeply negative margins indicate the business has not achieved durable profitability. Reported anomalies in gross profit reduce confidence in earnings quality, complicate forecasting and strategic planning, and elevate execution risk until clean, reproducible margins appear.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $8.58M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Nov 03, 2026 which is in 111 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Jun 15, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 130,017,560 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.857%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.62% Other Institutional Investors
99.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---